Multiple Sclerosis (MS) affects more than 2.3 million people worldwide; March is Multiple Sclerosis Education Awareness Month®, supported by the Multiple Sclerosis Foundation, with the theme, “MS...
Congrats to the Black Swan Analysis team for being nominated for this year’s BOBI award for the 'Agency I would most like to work with'. The competition for the top prize is looking tough this year,...
Access to the Epiomic Hospital Procedure data for the USA and European Region is now available. As part of our core Epiomic database offering to healthcare clients, we have now made available on-line...
https://www.youtube.com/watch?v=tXrtIQ1SUVI
In this article, Christopher Ehinger questions whether rare diseases are a viable option for the pharma industry. He looks at the total number of approvals and orphan drug designations in the US...
Christopher Ehinger of Black Swan Analysis explores one of the key trends in the pharma industry at the moment: defining patient populations. He believes that in order to be successful in the...
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem.
Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharma forecasting.
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast
*In the run up to Forecasting Europe [1] in Berlin in June, eyeforpharma asked some of our key speakers for their ins* [1] http://www.eyeforpharma.com/forecastingeu/
